RyboDyn has announced the discovery of a new proteome and the successful closing of a $4 million pre-seed financing round to advance its mission of targeting the dark proteome for the development of novel immunotherapies. The round was co-led by Genedant Capital and SeaX Ventures, with significant participation from SOSV and Swell VC as part of the investment syndicate.